Clinical Approaches and Emerging Therapeutic Horizons in Primary Hyperoxaluria
Journal of Clinical Medicine · 23.01.2026 · 15 (3) · 940
DOI: 10.3390/jcm15030940 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.01.2026. Verfasst von Ruth Martínez-Galindo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Hospital Universitario La Paz, 28046 Madrid, Spain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primary hyperoxalurias (PHs) are rare autosomal recessive disorders characterized by overproduction of oxalate, a metabolic end product that readily forms calcium oxalate crystals. Excess hepatic oxalate leads to recurrent kidney stones, nephrocalcinosis, and progressive renal injury, often culminating in end-stage kidney disease (ESKD). Once renal clearance declines, systemic oxalate accumulation can cause multisystem deposition. PH encompasses three types—PH1, PH2, and PH3—caused by deficiencies in the hepatic enzymes AGT, GRHPR, and HOGA1, respectively, resulting in accumulation of glyoxylate and subsequent oxalate overproduction. Clinical presentation varies from infantile oxalosis to adult-onset recurrent nephrolithiasis, with PH1 generally being the most severe. Diagnosis relies on urinary oxalate measurements, plasma oxalate in advanced chronic kidney disease, urinary metabolite profiling, imaging, and genetic testing. Management includes hyperhydration, citrate supplementation, pyridoxine for responsive PH1 patients, dialysis and transplantation when required, while RNA interference therapies targeting glycolate oxidase or LDHA have demonstrated substantial biochemical efficacy in PH1 and represent promising emerging therapeutic options, although long-term clinical outcome data remain limited and broader applicability to other PH types is still under investigation. Future strategies focus on modulating intestinal oxalate absorption, gut microbiome therapies, oxalate-degrading enzymes, and novel gene-editing approaches. Early diagnosis and individualized management are critical to prevent kidney injury and systemic oxalosis. In this review, we summarize the genetic, biochemical, and clinical features of PH and discuss current and emerging therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
- Urology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
ORCID-Profile: María Campuzano-Pérez, María Del Pilar Aguilar-Ramírez, Amir Shabaka
Zitieren
APA
Martínez-Galindo, R., Campuzano-Pérez, M., Konstantouli, A., Aguilar-Ramírez, M. D. P., Rodríguez, J. A. M., Abad-López, P., Shabaka, A., & Cansino, R. (2026). Clinical Approaches and Emerging Therapeutic Horizons in Primary Hyperoxaluria. Journal of Clinical Medicine, 15(3), 940. https://doi.org/10.3390/jcm15030940
Vancouver
Martínez-Galindo R, Campuzano-Pérez M, Konstantouli A, Aguilar-Ramírez MDP, Rodríguez JAM, Abad-López P, et al. Clinical Approaches and Emerging Therapeutic Horizons in Primary Hyperoxaluria. Journal of Clinical Medicine. 2026;15(3):940. doi:10.3390/jcm15030940
BibTeX
@article{MartnezGalindo2026,
author = {Martínez-Galindo, Ruth and Campuzano-Pérez, María and Konstantouli, Afroditi and Aguilar-Ramírez, María Del Pilar and Rodríguez, Juan Antonio Mainez and Abad-López, Pablo and Shabaka, Amir and Cansino, Ramón},
title = {Clinical Approaches and Emerging Therapeutic Horizons in Primary Hyperoxaluria},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {3},
pages = {940},
doi = {10.3390/jcm15030940}
}
EUVIMED